ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data

Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.